Skip to main content
Premium Trial:

Request an Annual Quote

Eagle Names HB Technologies its Distributor in Central Europe

NEW YORK (GenomeWeb News) – UK Bioinformatics company Eagle appointed German software firm HB Technologies as its distributor in Central Europe under a deal announced today.

The products and services deal covers Germany, Austria, Switzerland, and Luxembourg and allows Eagle to "significantly" expand its reach in the German-speaking market. HB Technologies will "source new projects and opportunities" for Eagle, which will continue to carry out delivery and implementation work, the firms said.

Financial and other terms of the deal were not disclosed.

"Eagle views overseas representation as key to continued expansion of its already substantial international customer base," Eagle Chief Business Officer Richard Holland said in a statement. "With existing customers in the UK, USA, France, Belgium, Denmark, the Netherlands, Switzerland, Germany, Malaysia, and Singapore, Eagle is no stranger to the business of working across time zones and through language barriers."

Eagle is based in Cambridge, UK, and specializes in bioinformatics, and computational and systems biology. During the summer, it announced plans to raise $1.6 million in preparation of a launch of its cloud-based life sciences data analysis product and an expansion of its staff.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.